2. Search Result
Search Result
Results for "

maytansinoid

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Screening Libraries

6

Inhibitory Antibodies

5

Isotope-Labeled Compounds

1

Antibodies

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19792
    Mertansine
    Maximum Cited Publications
    27 Publications Verification

    DM1; maytansinoid DM1

    		 Microtubule/Tubulin ADC Payload Cancer
    Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine
  • HY-132258A
    Mirvetuximab soravtansine (solution)
    3 Publications Verification

    IMGN853 (solution)

    		 Antibody-Drug Conjugates (ADCs) Antifolate Cancer
    Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141). Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
    Mirvetuximab soravtansine (solution)
  • HY-P99542
    Tusamitamab ravtansine

    SAR-408701; HuMAb2-3-SPDB-DM4

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
    Tusamitamab ravtansine
  • HY-141606
    Anetumab ravtansine

    BAY 94-9343

    		 Microtubule/Tubulin Antibody-Drug Conjugates (ADCs) Cancer
    Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
    Anetumab ravtansine
  • HY-141607
    Indatuximab ravtansine

    BT-062; nBT062-DM4

    		 Antibody-Drug Conjugates (ADCs) Bacterial Cancer
    Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
    Indatuximab ravtansine
  • HY-132262
    Lorvotuzumab mertansine

    IMGN-901; BB-1090

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity .
    Lorvotuzumab mertansine
  • HY-139441
    DM21

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936 .
    DM21
  • HY-148870
    Maytansinoid B

    		ADC Payload Cancer
    Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form antibody-drug conjugates (ADCs). Maytansinoids are known as antimitotic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis .
    Maytansinoid B
  • HY-130080
    DM3

    maytansinoid DM3

    		 ADC Payload Microtubule/Tubulin Cancer
    DM3 (Maytansinoid DM3), a Maytansine (HY-13674) analog bearing disulfide or thiol groups, and is a tubulin inhibitor. DM3 a cytotoxic moiety of antibody-drug conjugates (ADCs) .
    DM3
  • HY-100128
    DM1-SMe

    		Microtubule/Tubulin ADC Payload Cancer
    DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin .
    DM1-SMe
  • HY-136261
    DM1-PEG4-DBCO

    		Drug-Linker Conjugates for ADC Cancer
    DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DM1-PEG4-DBCO
  • HY-P990027
    Izeltabart

    IMGC-936 antibody; MGA021

    		 ADC Antibody MMP Cancer
    Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine). Izeltabart can be used in the study of cancer .
    Izeltabart
  • HY-W074975
    CL 5343

    5-Amino-1,3,4-thiadiazole-2-sulfonamide

    		 Carbonic Anhydrase Cancer
    CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is a selective inhibitor of carbonic anhydrase B (HCA-B) and isoforms I, II, IV, and VII. CL 5343 has a Ki of 7.9 nM for hCA II. CL 5343 acts as a CA9 ligand to achieve targeted delivery of maytansine to the cell membrane of SKRC52 renal cancer cells. CL 5343 is useful in the development of therapeutics for diseases associated with CA overactivity, such as glaucoma, epilepsy, and cancer .
    CL 5343
  • HY-114256
    EC1169

    		PSMA Cancer
    EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to PSMA-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .
    EC1169
  • HY-148818
    S-Me-DM4
    1 Publications Verification

    		 ADC Payload Others
    S-Me-DM4 is a metabolite of DM4 S-methylated by intracellular enzyme. DM4 (HY-100503) is a microtubule-depolymerizing maytansinoid with strong cytotoxicity. DM4 can be used as an ADC Cytotoxin molecule .
    S-Me-DM4
  • HY-100504
    S-methyl DM1

    		Microtubule/Tubulin ADC Payload Cancer
    S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a Kd of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects .
    S-methyl DM1
  • HY-100503
    Maytansinoid DM4

    		ADC Payload Cancer
    Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC .
    Maytansinoid DM4
  • HY-136260
    DBCO-PEG4-Ahx-DM1

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Ahx-DM1
  • HY-151559
    Zn-DPA-maytansinoid conjugate 1

    		Checkpoint Kinase (Chk) STAT CXCR CCR Cancer
    Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an "inflamed hot tumor" .
    Zn-DPA-maytansinoid conjugate 1
  • HY-143985S
    Maytansinoid DM4 impurity 5-d6

    		Drug Metabolite Isotope-Labeled Compounds Others
    Maytansinoid DM4 impurity 5-d6 is the deuterium labeled Maytansinoid DM4 impurity 5 .
    Maytansinoid DM4 impurity 5-d6
  • HY-143993S
    Maytansinoid DM4 impurity 3-d6

    		Drug Metabolite Isotope-Labeled Compounds Others
    Maytansinoid DM4 impurity 3-d6 is the deuterium labeled Maytansinoid DM4 impurity 3 .
    Maytansinoid DM4 impurity 3-d6
  • HY-143992S
    Maytansinoid DM4 impurity 2-d6

    		Drug Metabolite Isotope-Labeled Compounds Others
    Maytansinoid DM4 impurity 2-d6 is the deuterium labeled Maytansinoid DM4 impurity 2 .
    Maytansinoid DM4 impurity 2-d6
  • HY-W074975R
    CL 5343 (Standard)

    5-Amino-1,3,4-thiadiazole-2-sulfonamide (Standard)

    		 Carbonic Anhydrase Reference Standards Cancer
    CL 5343 (Standard) is the analytical standard of CL 5343. This product is intended for research and analytical applications. CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonic anhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .
    CL 5343 (Standard)
  • HY-148528
    SC-VC-PAB-N-Me-L-Ala-Maytansinol

    		Others Cancer
    SC-VC-PAB-N-Me-L-Ala-Maytansinol (compound B1) can be used to synthesis MCC-Maytansinoid A. SC-VC-PAB-N-Me-L-Ala-Maytansinol can be used as a control compound for the cancer research .
    SC-VC-PAB-N-Me-L-Ala-Maytansinol
  • HY-145663
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM

    		Drug-Linker Conjugates for ADC Cancer
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a agent-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety .
    HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
  • HY-19792S2
    Mertansine-d3

    DM1-d3; maytansinoid DM1-d3

    		 Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload Cancer
    Mertansine-d3 (DM1-d3) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine-d3
  • HY-100128R
    DM1-SMe (Standard)

    		Microtubule/Tubulin Reference Standards ADC Payload Cancer
    DM1-SMe (Standard) is the analytical standard of DM1-SMe (HY-100128). This product is intended for research and analytical applications. DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin .
    DM1-SMe (Standard)
  • HY-19792S
    Mertansine-13C,d3

    DM1-13C,d3; maytansinoid DM1-13C,d3

    		 Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload Cancer
    Mertansine- 13C,d3 (DM1- 13C,d3) is the 13C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine-13C,d3
  • HY-P991940
    JBH492 Antibody

    		ADC Antibody CCR Cancer
    JBH492 Antibody is a humanized, Fc-silenced anti-CCR7 IgG1 antibody. JBH492 Antibody can generate antibody drug conjugate (ADC) (JBH492) with a maytansinoid microtubule DM4 (HY-12454). JBH492 Antibody can be used for the study of lymphoma .
    JBH492 Antibody
  • HY-P991906
    TRPH-222 Antibody

    CD22-4AP Antibody; CAT-02-106 Antibody

    		 ADC Antibody CD22 Cancer
    TRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma) .
    TRPH-222 Antibody
  • HY-185483
    AMG-172

    		Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Microtubule/Tubulin Cancer
    AMG-172 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonal anti-CD27L antibody conjugated to DM1 (HY-19792) via the non-cleavable linker MCC. AMG-172 releases the intracellular active component Lysine-MCC-DM through catabolism. Lysine-MCC-DM inhibits the assembly and disassembly dynamics of Microtubule and induces cell arrest at metaphase. AMG-172 can be used for research on relapsed/refractory clear cell renal cell carcinoma .
    AMG-172

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: